Will ketamine help my focus?

There is no published clinical evidence that ketamine improves the core attention or focus problems of ADHD. If your focus difficulties are being worsened by depression or anxiety, treating those conditions may indirectly help concentration, motivation, and follow-through. But that is not the same as treating ADHD itself, and we will not promise you a focus benefit from ketamine.

Can I keep my Adderall, Vyvanse, or other ADHD medications?

Generally yes. We do not ask you to stop your prescribed ADHD medications. During screening we review your stimulant dose, blood pressure history, and cardiovascular risk factors, because both ketamine and stimulants can transiently raise heart rate and blood pressure. Continuous anesthesia-level monitoring during the infusion lets us track those changes safely. Never start, stop, or change a medication without talking to your prescribing provider.

Is the overlap between ADHD and depression actually real?

Yes. The landmark Kessler et al. study in the American Journal of Psychiatry (2006) found adults with ADHD have roughly a 19 percent rate of co-occurring major depression and around a 47 percent rate of co-occurring anxiety disorders. That is far higher than the general population. So when someone with ADHD also carries depression or anxiety, the overlap is well documented and the comorbid condition is often what is treatable here.

Should I get a formal ADHD evaluation before considering ketamine?

If you suspect undiagnosed ADHD, a formal evaluation is the right first step, and that is a separate workup we would refer you out for. Knowing whether ADHD is part of your picture changes how a clinician interprets your depression, your anxiety, and your day-to-day functioning. Ketamine is not the diagnostic answer here. A thorough psychiatric assessment is.

Are there any clinical trials of ketamine for ADHD?

Honestly, no. There is no published, well-designed randomized trial of ketamine for core ADHD symptoms that we would cite to guide a treatment decision. Some preclinical research describes interactions between the NMDA glutamate system and dopamine pathways relevant to attention, but that is mechanism interest, not clinical evidence. We will not present mechanism speculation as if it were proof of benefit.

Ketamine and ADHD: What the Research Does and Doesn't Say

Why ADHD itself is not a ketamine indication

We get this question often, so let's start with the clearest possible answer. Ketamine is not a treatment for ADHD. It is not approved for ADHD, it is not in clinical guidelines for ADHD, and there is no body of randomized controlled trials showing it improves the core ADHD symptoms of inattention, hyperactivity, or impulsivity. Anyone telling you otherwise is overpromising.

What does exist is a real comorbidity story. The DSM-5-TR (American Psychiatric Association, 2022) defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity that begins before age 12 and impairs functioning across multiple settings. That diagnostic frame matters because adult ADHD almost never travels alone. It frequently arrives wrapped in depression, anxiety, sleep disruption, and rejection-sensitive distress. Those companions are sometimes treatable with ketamine. ADHD itself is not.

This article is about that line. We will walk through the comorbidity data, the mechanism research that has researchers interested in NMDA-glutamate pathways, and what we will and will not treat at our clinic. Ketamine is FDA-approved as an anesthetic, and any psychiatric or pain use of it is off-label.

The comorbidity picture: ADHD, depression, and anxiety

The most cited dataset on adult ADHD comorbidity comes from the National Comorbidity Survey Replication. A Kessler et al. analysis published in American Journal of Psychiatry (2006) reported that adults meeting criteria for ADHD had:

A 12-month rate of major depressive disorder of roughly 19%, several times the general-population rate
A 12-month rate of any anxiety disorder of roughly 47%
Substantially elevated rates of substance use disorders compared to adults without ADHD

Read that again. Nearly half of adults with ADHD have a co-occurring anxiety disorder in any given year. About one in five has co-occurring major depression. These are not rare overlaps. They are the typical clinical picture, and they are the part of the picture that ketamine research is actually about.

When someone with ADHD comes to us asking whether ketamine could help, what we are usually evaluating is the depression or the anxiety, not the ADHD. The body of evidence on ketamine for anxiety and on treatment-resistant depression is what becomes relevant. The ADHD diagnosis stays where it is, managed by the prescriber who knows it best.

What the depression evidence actually shows

The ketamine antidepressant evidence base is substantial. Murrough et al., publishing in American Journal of Psychiatry (2013), ran a randomized active-control trial comparing IV ketamine to midazolam in patients with treatment-resistant depression. At 24 hours, response rates were 64% in the ketamine group versus 28% in the midazolam group. That gap is large enough, and replicated enough across subsequent trials, that ketamine is now a recognized off-label option for treatment-resistant depression. Spravato (esketamine) carries an FDA approval for treatment-resistant depression and for major depressive disorder with acute suicidal ideation, while IV ketamine itself remains off-label for psychiatric use.

None of that data, however, is data about ADHD. The trial populations were defined by depression. The outcome measures were depression scales. If a person carries both ADHD and major depression, the depression component is the one the evidence supports treating. If their depression lifts, secondary improvements in concentration, energy, motivation, and follow-through often follow, because depression is itself a focus and energy disorder. But that is depression treatment indirectly helping cognition. It is not ADHD treatment.

How NMDA and dopamine systems interact: mechanism only

Here is where some hope-driven internet content overreaches, so we will be careful. Ketamine works primarily as an NMDA receptor antagonist and triggers downstream glutamate-AMPA-mediated synaptic plasticity, as described in Krystal et al.'s mechanism review work in Biological Psychiatry (2013) and the broader neuropsychopharmacology literature. ADHD, on the other hand, is a condition where dopamine and norepinephrine signaling in the prefrontal cortex are central to the pathophysiology, which is why stimulants like methylphenidate and amphetamines work.

Preclinical neuroscience has described interactions between NMDA glutamate signaling and dopaminergic systems in the prefrontal cortex. That is real and that is interesting. Ketamine brain research continues to map how rapid synaptic remodeling reshapes circuits relevant to mood, motivation, and cognition. Researchers are looking at whether NMDA modulation might one day have a role in attention disorders.

But the leap from "preclinical mechanism interaction" to "ketamine treats ADHD" is exactly the leap we will not make. Mechanism interest is not clinical evidence. Until there are well-designed randomized trials with ADHD-specific endpoints, frame anything you read about ketamine and ADHD focus as hypothesis, not therapy.

Rejection-sensitive dysphoria and the depression overlap

Many adults with ADHD describe an intense pattern of emotional pain in response to perceived criticism or rejection. The community calls it rejection-sensitive dysphoria. It is not a formal DSM-5-TR diagnosis, and clinicians debate whether it is a discrete phenomenon, a feature of the underlying ADHD emotional dysregulation, or a manifestation of co-occurring depression and anxiety.

What we can say from clinical experience is that the depressive and anxious symptoms that often cluster around this pattern are sometimes responsive to ketamine. If chronic shame, hopelessness, or anhedonia is making everything worse, treating that depressive layer can lower the temperature on a person's whole emotional system. Ketamine's effect on neuroplasticity and glutamate signaling may help that depressive component shift. That is again a depression story, not an ADHD story, but for someone living inside both, the distinction can matter less than the relief.

We say "may help" deliberately. Ketamine for psychiatric conditions is off-label, response is variable, and not every person benefits. Some people do not respond at all. We cannot predict in advance who will and who will not.

Stimulant interactions and how we screen

If you take Adderall, Vyvanse, Concerta, Ritalin, Strattera, Wellbutrin, or another medication used in ADHD treatment, our consultation will cover that. We do not ask you to stop your prescribed ADHD medications to receive ketamine. The two medication classes are not categorically incompatible. What they share is the ability to transiently raise heart rate and blood pressure, which is why screening matters.

During screening we review your cardiovascular history, current vitals, dosing, and any history of arrhythmia, hypertension, or panic-related cardiac symptoms. During the infusion itself, monitoring is continuous. Marla Peterson, CRNA oversees every infusion, with anesthesia-level monitoring of pulse oximetry, blood pressure, and heart rate. If you want a deeper look at our safety setup, our safety overview walks through it in detail.

Important: never stop, lower, or change your ADHD medications around an infusion without first talking to your prescribing provider. We coordinate, we do not override.

What we will treat, and what we will not

To make this concrete:

What we treat: the depression that often co-occurs with ADHD, the anxiety that often co-occurs with ADHD, PTSD, OCD, and select chronic pain conditions. Ketamine for psychiatric and pain indications is off-label, and we say so.
What we do not treat: ADHD itself. Inattention, executive dysfunction, working memory problems, time blindness, and hyperactivity are not on the list of things we are claiming ketamine improves. If those are your primary concerns, ketamine is not the right tool.
What we will not say: that ketamine is a focus drug, that it replaces stimulants, that it cures ADHD, or that mechanism research equals clinical proof. None of those statements is supported by current evidence, and several of them are myths we have written about elsewhere in our myths and misconceptions piece.

This is also why we are wary of the "ketamine for everything" pitch you sometimes see online. The evidence is condition-specific, the response is individual, and the right treatment for ADHD is the treatment a qualified ADHD clinician recommends after a proper evaluation.

When an ADHD evaluation is the right next step instead

If you have never been formally evaluated for ADHD and you suspect you might have it, the right move is a comprehensive psychiatric or neuropsychological assessment. That is a workup we would refer you out for, not perform ourselves. A real ADHD evaluation includes structured interview, validated rating scales, developmental history, and ruling out conditions that mimic ADHD, including untreated depression, anxiety, sleep disorders, and substance use.

Sometimes, after that evaluation, the answer is yes, you have ADHD, and stimulant medication or a behavioral intervention is the right next step. Sometimes the answer is that what looked like ADHD is actually severe depression flattening your cognition, and that is where ketamine evidence becomes relevant. Sometimes it is both, and care has to be coordinated.

If you have a clear ADHD diagnosis, you are stable on stimulants or non-stimulants, and what you are dealing with on top of that is depression or anxiety that has not budged with standard treatment, that is a conversation we are well positioned to have. We will be honest about what ketamine does and does not do. We will not overpromise focus benefits. And we will defer to your prescribing clinician on anything ADHD-related.

Honest expectations about cost and access

Insurance typically does not cover IV ketamine for off-label psychiatric uses, including the depression and anxiety that often accompany ADHD. At Music City Ketamine, sessions are $475 each, and we are transparent about that from the first conversation. Most patients pursuing depression or anxiety protocols do an induction series and then assess. We do not bill insurance for off-label ketamine, and we do not pretend the cost is trivial.

Our team includes Marla Peterson, CRNA, who provides the clinical anesthesia oversight, and our therapy dogs Walter White and Wilma, who do not provide medical care but reliably lower the temperature of the room. The treatment environment is private, calm, and built around the assumption that people walking through the door have already had a hard time finding care that fits.

The bottom line

Ketamine is not an ADHD treatment. We will not pretend otherwise. The honest version of this story is that adult ADHD has a high comorbidity rate with depression and anxiety, those comorbid conditions are sometimes responsive to ketamine, and the line between treating the comorbidity and treating ADHD has to stay clear. NMDA-glutamate research and dopamine pathway interactions are interesting at a mechanism level, but mechanism interest is not the same as clinical proof. If you are weighing this decision, the right starting move is a real evaluation of what you are actually trying to treat.